FeNNix
About FeNNix
FeNNix-Bio1 is a quantum AI foundation model developed by Qubit Pharmaceuticals and Sorbonne University that transforms molecular simulations across biomolecular and pharmaceutical research. Trained entirely on synthetic quantum chemistry data, FeNNix-Bio1 integrates high-accuracy quantum methods including Density Functional Theory (DFT), Quantum Monte Carlo (QMC), and Configuration Interaction (CI) to build comprehensive generalizable representation of interatomic forces. Development enabled by exascale high-performance computing resources from GENCI, EuroHPC, and Argonne. Can be trained in few hours using standard GPU whereas other AI models require weeks of supercomputing time. Enables reactive molecular dynamics simulations at scale and accuracy previously unattainable, including formation and breaking of chemical bonds, proton transfer, and quantum nuclear effects. Applications extend beyond pharmaceuticals to industrial enzymes, desalination membranes, next-generation batteries, and green chemistry. Qubit Pharmaceuticals based in Paris and Boston with team over 60 people from 18+ nationalities.
2025 Developments: The company continues to enhance its quantum software platform and developer tools in 2025. Focus remains on improving algorithm efficiency and expanding use case applications. Active engagement with the quantum developer community drives product evolution.
Company Information
- Founded: 2020
- Country: France
- Website: https://www.qubit-pharmaceuticals.com
- Categories: quantum chemistry, quantum ai, quantum software
Key People
Qubit Pharmaceuticals & Sorbonne University Team
Related Companies
Explore other quantum computing companies in similar categories or regions.